ConductScience.org, home

Gene · 211

ALAS1: 5'-aminolevulinate synthase 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. ALAS1: 5'-aminolevulinate synthase 1. Genes, record 211. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/211

On this page

Gene

Symbol
ALAS1
HGNC
Name
5'-aminolevulinate synthase 1
HGNC
NCBI Gene ID
211
NCBI Gene
HGNC ID
HGNC:396
HGNC
Ensembl
ENSG00000023330
NCBI Gene
Aliases
ALAS, ALAS-H, ALAS3, ALASH, MIG4
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P131965-aminolevulinate synthase, non-specific, mitochondrial6400Ensembl, GeneID, HGNC

Source UniProt

Patents105

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1437233P13196Espacenet
JP 2026004568 A2026-01-1437234P13196Espacenet
JP 2026004568 A2026-01-1437236P13196Espacenet
JP 2026004568 A2026-01-1437237P13196Espacenet
EP 4650780 A22025-11-194604P13196Espacenet
EP 4641201 A22025-10-294174P13196Espacenet
EP 4612154 A12025-09-101P13196Espacenet
JP 2025517969 A2025-06-124174P13196Espacenet
JP 2025517970 A2025-06-124604P13196Espacenet
JP 2025062604 A2025-04-14363P13196Espacenet

1 to 10 of 105

See all 105 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
GIVOSIRANCHEMBL42977605-aminolevulinate synthase mRNA RNAi inhibitorRNAI INHIBITORChEMBL
GIVOSIRAN SODIUMCHEMBL45942655-aminolevulinate synthase mRNA RNAi inhibitorRNAI INHIBITORChEMBL

Trials4

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT04056481GIVOSIRANClinicalTrials.gov
NCT03338816GIVOSIRANPHASE32020-02-11ClinicalTrials.gov
NCT02949830GIVOSIRANPHASE1/PHASE22024-03-12ClinicalTrials.gov
NCT02452372GIVOSIRANPHASE1ClinicalTrials.gov

NIH grants868

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleALAS1 papersNewest fiscal year
U54DK110858Center for Iron & Heme Disorders at the University of Utah102025
P30CA016672Cancer Center Support Grant52025
P30CA008748Cancer Center Support Grant42025
R01DK074797Inter-organ signaling in heme metabolism and organismal homeostasis.42025
ZIAHD001602Regulation Of Intracellular Iron Metabolism42025
ZIAHD008814Mammalian iron-sulfur cluster biogenesis42025
KL2TR001879Institutional Career Development Core32025
P30CA093373Cancer Center Support Grant P3032025
P30ES010126UNC Center for Environmental Health and Susceptibility32025
R01CA225958Novel bioengineered microRNA therapeutics for lung cancer32025

1 to 10 of 868Source NIH's project files

See all 868 nih grants

Papers1,411

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Single-center real-world experience with givosiran for management of acute intermittent porphyria.Mol Genet Metab202642804985PubTator, text miningPubMed
A mitochondrial insertion directs substrate selection and engagement by the protein unfoldase ClpX.J Biol Chem202642710671PubTator, text miningPubMed
Case Report: A Previously Healthy Young Woman With Lethal, Unremitting Metabolic Acidosis: Could a Novel Variant in ALAS2 Be the Culprit?Case Rep Pathol202642676669PubTator, text miningPubMed
Glycine improves boar sperm linear motility by promoting heme biosynthesis to regulate mitochondrial energy metabolism.Theriogenology202642667783PubTator, text miningPubMed
The Role of Cytochrome P450 Holoenzyme Metabolism in the Origin of Neuropathologies.Int J Mol Sci202642589625PubTator, text miningPubMed
An adaptor for feedback regulation of heme biosynthesis by a mitochondrial protease.Science202642531414PubTator, text miningPubMed
Treating a patient with ADP porphyria through suppression of both hepatic and erythroid ALA production.Orphanet J Rare Dis202642443962PubTator, text miningPubMed
Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases.Orphanet J Rare Dis202642271396PubTator, text miningPubMed
Evening circadian preference as a potential risk factor for cancer-depression comorbidity: a comprehensive analysis from population cohort to molecular insights.J Adv Res202642248509PubTator, text miningPubMed
Single-cell mapping of regulatory DNA-protein interactions.Cell202642242226PubTator, text miningPubMed

1 to 10 of 1,411

See all 1,411 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/211

GET https://conductscience.org/api/genes/v1/211/patents?page=2